Teva Pharmaceutical Reports $4.48 Billion Revenue in Q3 2025, 3% Year-Over-Year Increase

Teva Pharmaceutical Industries Ltd. reported a net revenue of $4.48 billion for the third quarter of 2025, marking a 3% increase from $4.33 billion in the same period last year. The company's gross profit rose to $2.30 billion, up 7% from $2.15 billion, resulting in a gross profit margin of 51.4%, compared to 49.6% in the prior year. Teva's operating income was $882 million, a significant recovery from an operating loss of $51 million in the third quarter of 2024. The net income attributable to Teva was $433 million, reversing a net loss of $437 million from the previous year.

In terms of segment performance, the U.S. segment generated $2.48 billion in revenue, a 12% increase year-over-year, with a segment profit of $937 million, up 25%. Conversely, the Europe segment saw a slight decline in revenue to $1.24 billion, down 2%, with a segment profit of $303 million, a decrease of 19%. The International Markets segment reported revenues of $557 million, down 9%, with a segment profit of $95 million, a 13% decline. The overall increase in revenue was attributed to higher sales of AUSTEDO and generic products, including biosimilars, in the U.S. market.

Teva's strategic initiatives included the ongoing execution of its "Pivot to Growth" strategy, which aims to enhance its innovative portfolio and optimize operations. The company is also in the process of divesting its active pharmaceutical ingredient (API) business, a move aligned with its growth strategy. The divestment discussions have faced challenges, but Teva remains committed to this strategic direction. Additionally, Teva has launched several new products, including the generic version of liraglutide injection, which is expected to contribute to future revenue growth.

Operationally, Teva's total employee count was reduced as part of its restructuring efforts, which are expected to yield cost savings of approximately 8% of its workforce by the end of 2027. The company recorded $256 million in research and development expenses for the third quarter, a 7% increase from the previous year, reflecting its commitment to innovation. Teva's cash flow from operating activities was $369 million, down from $693 million in the same quarter last year, primarily due to timing of sales and collections.

Looking ahead, Teva anticipates continued revenue growth driven by its innovative product pipeline and strategic partnerships. The company is also closely monitoring macroeconomic factors, including currency fluctuations and inflation, which could impact its financial performance. Teva's management remains optimistic about achieving its operational and financial targets as it navigates the evolving pharmaceutical landscape.